Abstract
A National Institutes of Health (NIH) workshop was convened in Bethesda, MD, with representative scientific leaders in the field of proteomics. The workshop aimed to articulate how the biomedical research community can capitalize on recent technological advances to advance human proteomics. This report summarizes the discussions regarding the transition from genomic blueprints to functional proteomic realities.
Introduction: Beyond the Genomic Blueprint
While the Human Genome Project successfully provided a "parts list" for human biology, DNA alone remains insufficient to explain the dynamic complexity of disease. Proteins are the functional machines of the cell and the primary targets for most therapeutics. However, a significant gap exists between genomic knowledge and phenotypic expression. The proteome is inherently more complex than the genome—it is dynamic, cell-type specific, and subject to thousands of post-translational modifications (PTMs).
Technological Tipping Points
The field of proteomics has reached a "disruptive" technological milestone. Leading laboratories can now identify and quantify approximately 10,000 protein products in a single specimen, likely representing the entire expressed proteome of a single cell type. This capability marks a shift from one-off studies to a systematic, unbiased approach similar to the Human Genome Project.
Mass Spectrometry and Precision
Two primary approaches dominate the landscape:
- Shotgun Proteomics: Used for the exploratory discovery of thousands of proteins.
- Selected Reaction Monitoring (SRM): A targeted, highly precise method for quantifying specific biomarkers. Notably, 99% of the ~20,300 human gene-coded proteins have already had their mass spectra determined and shared via the SRM Atlas.
Mapping the Interactome
Understanding the "interactome"—the complex wiring diagram of macromolecular interactions—is essential for deciphering cellular signaling. Currently, the scientific community has mapped only about 20% of the high-quality interactions in the human reference interactome. This leaves an 80% "dark matter" of biology that must be explored to understand how signals are rerouted in diseases like cancer. Tools such as Cytoscape and BioGRID are increasingly used to visualize these networks.
Infrastructure and Multi-Omics Integration
The advancement of the field relies on foundational resources that serve as the infrastructure for human proteomics:
- The Human Protein Atlas: An antibody-based map of tissue-specific protein expression.
- PeptideAtlas & SRM Atlas: Mass spectrometry-based repositories providing "fingerprints" for nearly all human proteins.
- Direct Integration: Combining mRNA expression data with protein abundance to observe how genetic variations (such as SNPs) manifest at the protein level.
Clinical Translation and P4 Medicine
Proteomics serves as the primary engine for "P4 Medicine": Predictive, Preventive, Personalized, and Participatory. By monitoring the proteome, clinicians can detect the transition from health to disease much earlier than with traditional methods. A successful precedent is OVA1, an FDA-cleared multivariate index assay for ovarian cancer, which demonstrates how complex proteomic signatures can navigate the regulatory hurdles of the FDA.
Challenges and Future Directions
Despite significant progress, several hurdles remain:
- Dynamic Range: Detecting low-abundance signaling molecules in complex fluids like blood remains a significant engineering challenge.
- PTM Mapping: Understanding the function of tens of thousands of phosphorylation and glycosylation sites is the next great frontier.
- Statistical Rigor: Researchers must avoid "high-dimensional data" traps where testing too many variables on small cohorts leads to false-positive biomarkers.
Future success depends on public-private partnerships to bridge the gap between academic discovery and the standardized requirements of clinical laboratories, ultimately creating a systematic roadmap for the Human Proteome Project to transform healthcare.
Summary updated